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Objectives. This study sought to assess the long-term prognostic
utility of dobutamine stress echocardiography in predicting fatal
and nonfatal cardiac events.
Background. Although dobutamine stress echocardiography
has improved sensitivity and specificity for detection of coronary
artery disease, little is known of its predictive value for long-term
cardiac events. Therefore, we followed up 120 consecutive patients
who underwent dobutamine echocardiography for suspected cor-
onary disease from March 1989 to August 1991.
Methods. All patients presenting for coronary angiography for
chest pain were eligible for recruitment. Follow-up was 100%
complete at 5 years (range 3.0 to 6.1). Cardiac events were defined
as cardiac death or nonfatal myocardial infarction or the need for
coronary revascularization (coronary angioplasty or bypass surgery).
Results. Positive (n 5 78) and negative (n 5 42) dobutamine
test groups differed in their rates of coronary artery bypass graft
surgery (37.2% vs. 9.5%, p < 0.001, respectively) and mortality. Of
26 total deaths, 22 occurred in the group with positive dobutamine
test results (28% vs. 9.5%, p < 0.018); all 7 cardiac deaths
occurred in this group as well (9% vs. 0%, p < 0.045). By
multivariate regression analysis, positive results on dobutamine
echocardiography remained independently predictive of future
cardiac death after left ventricular ejection fraction and other
clinical variables were accounted for.
Conclusions. A positive finding on dobutamine echocardiogra-
phy is an independent predictor of long-term cardiac mortality,
whereas a negative finding confers a significantly reduced likeli-
hood of cardiac death as much as 5 years from initial testing. We
conclude that dobutamine stress echocardiography can be used to
predict which patients with suspected coronary artery disease are
at low risk for cardiac death and do not require concurrent
nuclear or invasive testing.
(J Am Coll Cardiol 1997;29:969–73)
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Dobutamine stress echocardiography has been increasingly
used to detect coronary artery disease, assess myocardial
viability and predict cardiac risk in post-myocardial infarction
patients and before major noncardiac surgery (1–5). The
ability of dobutamine stress echocardiography to provide prog-
nostic information regarding future cardiac events has been
limited to 1- to 2-year follow-up studies (6,7). One- to 10-year
follow-up studies (8–10) of normal myocardial perfusion as-
sessed by exercise thallium testing have demonstrated an
excellent cardiac prognosis, with a likelihood of cardiac death
or infarction #1%/year. An excellent prognosis has also been
described (11–13) in long-term follow-up studies of coronary
angiography in patients with normal or minimal coronary
artery disease. However, although overall cardiac mortality
rates remained low in these angiographic studies, patients with
minimal or moderate disease had a significant increase in
mortality, with a marked downsloping in their cardiac survival
curve after 6 to 8 years (12–14). Dobutamine echocardiogra-
phy has correlated well with angiographic and scintigraphic
findings (1,2,15); however, its ability to predict cardiac events
over a similar long-term follow-up period has not been deter-
mined. We therefore prospectively assessed 120 consecutive
patients who underwent dobutamine stress echocardiography
to determine its prognostic utility for predicting cardiac events
over a 3- to 6-year period.
Methods
Patients. The methods and results of our initial studies
involving this same patient cohort have been described in
detail elsewhere (1,2). Eligibility for participation in the study
included patients presenting for coronary angiography to eval-
uate chest pain at the East Orange Veterans Affairs Medical
Center between March 1989 and August 1991. These patients
also had to successfully undergo dobutamine stress echocardi-
ography. Exclusion criteria included unstable angina, cardio-
myopathy, uncontrolled hypertension, significant valvular
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heart disease, known serious arrhythmia, congestive heart
failure and previous coronary artery bypass surgery. The final
cohort included 120 veterans (119 male; mean [6SD] age
66.9 6 9.6 years, range 47 to 95). Patients were classified into
two groups: 78 (65%) with positive and 42 (35%) with negative
dobutamine test results.
Baseline characteristics. At the time of dobutamine stress
echocardiography, baseline information regarding medical his-
tory and coronary risk factors were recorded for each patient
and included age, tobacco usage, diabetes, hypertension, an-
gina, family history of coronary artery disease, hypercholester-
olemia, congestive heart failure, previous myocardial infarc-
tion, cerebrovascular accident, percutaneous transluminal
coronary angioplasty and baseline left ventricular ejection
fraction determined from the apical four-chamber view using
the single-plane area–length method. Except for baseline left
ventricular ejection fraction, these baseline characteristics did
not differ significantly between the two patient groups (Table
1).
Cardiac catheterization. Left-sided cardiac catheterization
and coronary angiography were performed within 2 weeks of
dobutamine stress echocardiography in the standard manner.
Significant coronary artery disease was defined as .70%
reduction in the lumen diameter of any of the three major
epicardial coronary arteries or their primary branches, or
.50% reduction of the lumen diameter of the left main
coronary artery. Angiograms were reviewed in blinded manner
by two angiographers who had no knowledge of the results of
dobutamine echocardiography.
Dobutamine echocardiography. Dobutamine stress echo-
cardiography was performed using a Hewlett-Packard Sonos
500 echocardiography system and digitized on-line using a
Nova Microsonics, PreVue analyzer. After baseline images
were recorded, 2.5 mg/kg body weight per min of dobutamine
was infused in 3-min increments to a maximum of 40 mg/kg per
min. Images from the four standard views of the left ventricle
(parasternal long- and short-axis, apical four- and two-
chamber views) were recorded in a quad screen format and
stored on a 5.25-in. floppy disk for later analysis.
A positive dobutamine stress test result was defined as the
development of a new wall motion abnormality not present at
baseline. For those studies with baseline wall motion abnor-
malities, a positive study result consisted of one showing either
a higher grade wall motion abnormality in the baseline abnor-
mal segment (i.e., from hypokinetic to akinetic) or any new
wall motion abnormality in a different segment. Echocardio-
grams were read in blinder manner by two experienced observ-
ers who had no knowledge of the results of cardiac catheter-
ization. There was 94% interobserver and 96% intraobserver
agreement. Disagreements were resolved by consensus.
Patient follow-up. Follow-up data were obtained from di-
rect telephone contact, hospital and computer records and the
Beneficiary Identification and Record Locator Subsystem
(BIRLS) (16). BIRLS is a computerized database that identi-
fies veterans and their dependents who receive compensation,
pension, education and other Veterans Affairs benefits. The
accuracy rate is 95%. Follow-up was 100% complete for both
morbidity and mortality.
All patients were followed up for a mean of 5 years (range
3.0 to 6.1). Evaluated end points included death, myocardial
infarction, percutaneous transluminal coronary angioplasty
and coronary artery bypass graft surgery (Table 2). Deaths
were further classified as cardiac or noncardiac. Acute myo-
cardial infarction was verified by hospital records using stan-
dard criteria of history, electrocardiogram (ECG) and cardiac
enzyme levels.
Statistical analysis. Variables were compared using chi-
square analysis, with p , 0.05 considered significant. Logistic
regression was used to compare the strength of the association
of cardiac death with several other common clinical variables.
In this multivariate analysis, the predictive value of dobut-
amine stress echocardiography was considered in combination
with age, hypertension, angina, tobacco usage, diabetes, hyper-
cholesterolemia, previous myocardial infarction, congestive
heart failure, left ventricular ejection fraction ,40%, rest wall
motion abnormalities on echocardiography and family history
of coronary artery disease. The least significant variables were
removed from the model in a backward stepwise manner until
Table 1. Baseline Patient Characteristics
DSE1
(n 5 78)
DSE2
(n 5 42)
p
Value
Mean 6 SD age (yr) 68.3 6 8.0 65.8 6 7.7 NS
Tobacco use 25 (32.1%) 10 (23.8%) NS
Diabetes 21 (26.9%) 6 (14.3%) NS
Hypertension 36 (46.2%) 25 (59.5%) NS
Angina 36 (46.2%) 17 (40.5%) NS
Family history of CAD 6 (7.7%) 3 (7.1%) NS
Hypercholesterolemia 7 (9.0%) 5 (11.9%) NS
CHF 2 (2.6%) 1 (2.4%) NS
MI 21 (26.9%) 6 (14.3%) NS
CVA 1 (1.3%) 0 (0.0%) NS
PTCA 3 (3.8%) 1 (2.4%) NS
LVEF ,40% 13 (16.7%) 0 (0.0%) 0.005
Cath results
0 VD 3 (3.8%) 31 (73.8%) 0.0000
1 VD 23 (29.5%) 8 (19.0%) NS
2 VD 24 (30.8%) 3 (7.1%) 0.003
3 VD 28 (35.9%) 0 (0.0%) 0.00001
Data presented are number (%) of patients, unless otherwise indicated.
CAD 5 coronary artery disease; Cath 5 cardiac catheterization; CHF 5
congestive heart failure; CVA 5 cerebrovascular accident; DSE1/2 5 positive/
negative results on dobutamine stress echocardiography; LVEF 5 left ventric-
ular ejection fraction; MI 5 myocardial infarction; PTCA 5 percutaneous
transluminal coronary angioplasty; VD 5 vessel disease.
Abbreviations and Acronyms
BIRLS 5 Beneficiary Identification and
Record Location Subsystem
ECG 5 electrocardiogram
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only the two most significant variables remained as indepen-
dent predictors of cardiac death.
Kaplan-Meier survival curves were performed for all-cause
mortality, and equality of survival was compared using the
Mantel-Cox test.
Results
Coronary angiography. Cardiac catheterization revealed
that patients with positive dobutamine test results were signif-
icantly more likely to have multivessel coronary artery disease
(66.7% vs. 7.1%, p , 0.0000) (Table 1). Importantly, no
patient with three-vessel coronary artery disease had negative
dobutamine test results. In contrast, dobutamine echocardiog-
raphy was not a sensitive means of detecting patients with
single-vessel coronary artery disease. This lack of sensitivity
was demonstrated by 25.8% of patients with single-vessel
disease with negative dobutamine test results.
Clinical follow-up. Cardiac and all-cause mortality were
significantly higher in patients with positive dobutamine test
results (9.0% vs. 0.0%, p , 0.045 and 28.2% vs. 9.5%, p ,
0.018, respectively) (Table 2). All seven cardiac-related deaths
occurred in the group with positive dobutamine test results
(five secondary to coronary artery disease, two due to conges-
tive heart failure). Of 19 noncardiac deaths, 7 were due to
malignancy, 2 to renal disease, 2 to liver disease, 2 to pneu-
monia, 2 to unknown causes (both in the group with positive
dobutamine test results) and 1 each due to AIDS, stroke,
cellulitis and gastrointestinal bleeding. Patients with positive
dobutamine test results were more likely to undergo coronary
artery bypass surgery than those with negative dobutamine test
results (37.2% vs. 9.5%, p , 0.001). Coronary artery bypass
surgery and percutaneous transluminal coronary angioplasty
procedures were performed a mean of 14.8 and 11.8 months
after dobutamine echocardiography, respectively. The inci-
dence of nonfatal myocardial infarction and percutaneous
transluminal coronary angioplasty did not differ significantly
between the two groups.
Dobutamine echocardiography had a sensitivity and speci-
ficity of 78.8% and 51.9%, respectively, for identifying all
cardiac events; a sensitivity and specificity of 100% and 37.2%,
respectively, for identifying cardiac-related death; and a nega-
tive predictive value of 100% and 95.2%, respectively, for
cardiac death and myocardial infarction (Table 2).
Multivariate regression analysis showed that positive find-
ings on dobutamine echocardiography and an ejection fraction
,40% were the only independent variables associated with
cardiac death. Kaplan-Meier survival analysis revealed a sig-
nificant difference in cumulative percent survival between
groups (71.8% with positive vs. 90.5% with negative dobut-
amine test results, p 5 0.02) that became apparent at 3 years
into the follow-up period (Fig. 1).
Discussion
To our knowledge, this is the first report to describe the
5-year prognostic value of dobutamine echocardiography in
evaluating patients with coronary artery disease. Our data
demonstrate the ability of normal findings on dobutamine
echocardiography to predict which patients with a high pretest
probability of coronary artery disease are at low risk of
long-term fatal cardiac events. These findings are similar to
several long-term follow-up studies of cardiac and all-cause
mortality in patients with either normal exercise thallium
results or angiographically normal or minimally diseased cor-
onary arteries (Table 3). In these studies, patients with either
normal myocardial perfusion or #50% coronary lumen nar-
rowing had an annual cardiac mortality rate #0.5%/year and
an all-cause mortality rate #0.9%/year. Our study shows
similar results, with annual 5-year cardiac and all-cause mor-
tality rates of 0%/year and 1.9%/year, respectively.
Figure 1. Kaplan-Meier survival analysis of cumulative percent sur-
vival between groups. Solid line 5 negative dobutamine test results;
dashed line 5 positive dobutamine test results. Curves differed
significantly (p 5 0.02).
Table 2. Events After Dobutamine Stress Echocardiography
DSE1
(n 5 78)
[no. (%) of pts]
DSE2
(n 5 42)
[no. (%) of pts]
p
Value Sensitivity Specificity
Positive
Predictive
Value
Negative
Predictive
Value
All cardiac events 52 (66.7%) 14 (33.3%) 0.0005 78.8% 51.9% 66.8% 66.7%
MI 3 (3.8%) 2 (4.8%) 0.811 60.0% 34.8% 3.8% 95.2%
PTCA 13 (16.7%) 8 (19.0%) 0.743 61.9% 34.3% 16.7% 81.0%
CABG 29 (37.2%) 4 (9.5%) 0.001 87.9% 43.7% 37.2% 90.5%
Cardiac-related death 7 (9.0%) 0 (0.0%) 0.045 100% 37.2% 9.0% 100%
All deaths 22 (28.2%) 4 (9.5%) 0.018
CABG 5 coronary artery bypass graft surgery; pts 5 patients; other abbreviations as in Table 1.
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The finding that patients with positive dobutamine test
results were more likely to require future surgical revascular-
ization is consistent with the ability of dobutamine echocardi-
ography to accurately distinguish between patients with mul-
tivessel versus lesser degrees of coronary disease. However, the
poor sensitivity of dobutamine echocardiography for detecting
patients with single-vessel coronary artery disease may help to
explain why this test was less predictive of the need for future
coronary angioplasty.
Although cardiac survival in the group with negative dobut-
amine test results was excellent, nonfatal myocardial infarction
occurred with a similar frequency in those with negative (4.8%)
or positive (3.8%) findings on dobutamine echocardiography.
This frequency is similar to that described in studies of patients
with either normal thallium exercise test results or coronary
lumen narrowing, where the majority of hard events (cardiac
death or nonfatal infarction) have been nonfatal infarctions
(8–13). Possible explanations for these events could include
either the progression of an existing lesion that was physiolog-
ically “silent” or the development of a new, obstructive lesion
within an artery with previously undetectable disease. Several
invasive studies (17–19) have demonstrated the development
of new, obstructive coronary lesions in areas of an artery with
only minor disease on initial angiography.
Study limitations. Some limitations should be considered
in interpreting this study. Because we did not know the number
of patients referred who may have had abnormal results on
previous exercise electrocardiography, the relative prognostic
value of the stress ECG together with wall motion analysis
could not be assessed. Also, because all patients in the study
had a high pretest probability for coronary artery disease by
virtue of their presentation with chest pain and selection for
cardiac catheterization, these results may not be applicable to
a more general referral population. A posttest referral bias can
not be eliminated from this study because dobutamine echo-
cardiographic results were available to the clinicians caring for
these patients. Finally, these results will need to be reproduced
in further studies involving a larger patient cohort before the
precise role of dobutamine stress echocardiography in long-
term cardiac risk stratification can be determined.
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